Abstract
Background Clostridium difficile infection (CDI) is an important cause of nosocomial diarrhea. Given the discrepancy in current treatment guidelines for mild CDI, we sought to evaluate the use of first-line vancomycin for the treatment of non-severe infection.
Methods We conducted a retrospective cohort study of all adult inpatients with first episode CDI at our institution from January 2013 to May 2018. CDI was defined as a positive C. difficile loop-mediated isothermal amplification assay, in conjunction with ≥3 type 5–7 stools on the Bristol stool scale. To evaluate the impact of first-line vancomycin treatment on adverse clinical outcomes in patients with first episode non-severe CDI, the initial vancomycin vs. initial metronidazole cohorts were first examined in an unadjusted logistic regression analysis for any combination of relapse, recurrence, and all-cause 30-day mortality, followed by an adjusted multivariable analysis.
Results A total of 737 cases were included. Patients had a median age of 72.3 years (Q1: 61.2, Q3: 83.3) and 628 (85.2%) were classified as non-severe CDI. Among patients with non-severe CDI (n = 628), relapse, recurrence, and mortality rates were 17.4%, 7.0%, and 11.4%, respectively, when treated with initial metronidazole, compared to 18.6%, 3.1%, and 7.8%, respectively, when treated with initial vancomycin. In an adjusted multivariable analysis, the use of first-line vancomycin for the treatment of non-severe CDI was associated with a reduction in recurrence or 30-day mortality (ORadj: 0.51; 95%CI: 0.28–0.94; P=0.03).
Conclusions Initial vancomycin was associated with reduced recurrence or all-cause 30-day mortality in the treatment of adult inpatients with first episode non-severe CDI. Our findings support the use of initial vancomycin for all C. difficile inpatients, irrespective of disease severity, as recommended by Infectious Diseases Society of America guidelines.
- Clostridium difficile
- vancomycin
- metronidazole
- relapse
- recurrence
- mortality
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The authors received no specific funding for this project.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocol was approved by the Hamilton Integrated Research Ethics Board (Project: 2018-3543). The Hamilton Integrated Research Ethics Board has categorized this retrospective cohort study as minimal risk, defined as no potential for negative impact on the health and safety of the participant, and waiver of consent for participation was obtained.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The datasets generated for the study are not publicly available due to the presence of personally identifiable information. Aggregate data, however, are presented in the manuscript within the Tables and Figure and are available from the corresponding author on reasonable request.
